Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug pipeline 3Q18

The third quarter saw a raft of first-in-class approvals, including the first RNA interference (RNAi) drug, the first nanobody, and a novel immunotoxin combining a CD22 Fv antibody fragment and an exotoxin. RNAi, antisense and small molecules achieved clinical milestones in hereditary transthyretin amyloidosis for both neuropathy and cardiomyopathy. Disappointing trial data presented a major setback for indoleamine 2,3-dioxygenase inhibitors in immuno-oncology.

FDA approvals by drug type

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. Drug pipeline 3Q18. Nat Biotechnol 36, 1132 (2018). https://doi.org/10.1038/nbt.4310

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing